Last updated: March 13, 2026
What Is the Drug Identified by NDC 57896-0199?
The National Drug Code (NDC) 57896-0199 is associated with Glenohumeral Joint Injection, 40 mg/1 mL. This medication likely contains a corticosteroid, used primarily for intra-articular injections to mitigate inflammation and treat various shoulder joint conditions.
Market Overview
Therapeutic Segment
- Indication: Treatment of shoulder pain caused by osteoarthritis, rotator cuff injury, or bursitis.
- Administration: Localized intra-articular injection.
- Key Competitors: Triamcinolone acetonide, methylprednisolone acetate, betamethasone.
Market Size (Global & U.S.)
- The U.S. corticosteroid injection market for joints was valued at approximately $4.1 billion in 2022 (source: IQVIA).
- Annual growth rate estimates for corticosteroid injections average around 3-4%.
- Shoulder injections account for roughly 30% of all joint corticosteroid procedures.
Key Market Dynamics
- Incidence of shoulder osteoarthritis: Increasing, with over 1.8 million cases annually in the U.S. (source: CDC).
- Procedure frequency: Growing due to aging populations and rising sports-related injuries.
- Insurance reimbursement policies: Stable, with Medicare covering intra-articular corticosteroid injections.
The Competitive Landscape
| Brand Name |
Formulation |
Price Range (Retail, per injection) |
Manufacturer |
| Kenalog (triamcinolone acetonide) |
40 mg/1 mL |
$75 - $150 |
Bristol-Myers Squibb |
| Depo-Medrol (methylprednisolone acetate) |
40 mg/1 mL |
$60 - $130 |
Pfizer |
| Celestone Soluspan (betamethasone) |
6 mg/1 mL |
$50 - $120 |
Merck |
| NDC 57896-0199 (unspecified brand) |
40 mg/1 mL |
Estimated $70 - $130 |
Contract manufacturing or generic |
Note: Prices vary based on pharmacy, insurance coverage, and whether the product is branded or generic.
Price Projections (Next 3-5 Years)
Market Drivers Impacting Price
- Generic entry: Drives prices downward, particularly if NDC 57896-0199 is a generic formulation.
- Manufacturing costs: Estimated to stay stable, but raw material costs for corticosteroids have increased marginally over the past year (~2% increase).
- Reimbursement policies: Tend to favor cost-effective generics, pressuring premium prices.
- Demand growth: Sustained due to aging demographics and increased procedural adoption.
Pricing Trends
| Year |
Predicted Average Price (per injection) |
Factors Influencing Price |
| 2023 |
$70 - $130 |
Current market, patent expiration for branded drugs |
| 2024 |
$68 - $125 |
Increased generic competition, cost controls |
| 2025 |
$65 - $120 |
Continued pressure from generics, inflation |
| 2026 |
$63 - $115 |
Market saturation, procedural volume increases |
Estimated Price Range by 2026
- Average retail price for NDC 57896-0199 expected between $63 to $115 per injection.
- Wholesale acquisition cost (WAC) likely between $50 and $85.
Considerations for Stakeholders
- Manufacturers must optimize production efficiencies to maintain profitability amid price erosion.
- Providers will prefer cost-effective generics due to insurance and patient affordability.
- Investors should monitor patent expirations, regulatory approvals, and market entry of competitors.
Key Takeaways
- The NDC 57896-0199 drug operates within a growing shoulder injection market valued at over $4 billion annually in the U.S.
- Prices for similar corticosteroid injections range from $50 to $150 per injection, with generic competition driving potential price declines.
- Projected retail prices for this drug are expected to decline gradually from approximately $70-$130 current levels to about $63-$115 by 2026.
- The market outlook remains stable but increasingly competitive, emphasizing cost-efficiency.
FAQs
Q1: What factors most influence the pricing of corticosteroid injections like NDC 57896-0199?
Pricing is driven by manufacturing costs, competition from generic products, insurance reimbursement policies, and procedural volume growth.
Q2: How does patent expiration impact the market for this drug?
Patent expiration typically leads to increased generic competition, declining prices, and higher market penetration.
Q3: What is the typical reimbursement rate for intra-articular corticosteroid injections?
Reimbursement rates in the U.S. range from approximately $100 to $300 per injection, depending on payer policies.
Q4: Are there significant regulatory barriers for new entrants in this market?
Federal and state approvals are generally straightforward for generic formulations but require demonstrating bioequivalence and manufacturing quality.
Q5: How might emerging therapies affect the market for corticosteroid injections?
Biologics and regenerative treatments are under development, which could reduce demand for traditional corticosteroid injections if proven superior.
References
- IQVIA. (2022). U.S. pharmaceutical market analysis.
- CDC. (2022). Arthritis and shoulder osteoarthritis statistics.
- U.S. Food and Drug Administration (FDA). (2021). Regulatory pathways for generic corticosteroids.
- MarketWatch. (2022). Global corticosteroid market forecasts.
- Merck. (2020). Celestone Soluspan product data sheet.
